Evaluation of Performance and Safety of KIO015 in Face Tissue Filling

Inclusion Criteria: * Subject with signs of cutaneous ageing on the face according to investigator's judgment. * Subject with dehydrated skin on the face (value \< 60 A.U with Corneometer®). * Subject having given freely and expressly his informed consent. * Subject, psychologically able to understand the study related information and to give a written informed consent. * Subject affiliated to a health social security system. * Female of childbearing potential must use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study and during all the study. * Female subjects of childbearing potential must have a negative pregnancy test at the inclusion. Exclusion Criteria: In terms of population * Pregnant or nursing woman or planning a pregnancy during the study. * Woman with menopause from less than 1 year or in perimenopause, without hormonal treatment. * Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship. * Subject in a social or sanitary establishment. * Subject participating to another research on human beings or being in an exclusion period for a previous study. * Subject having received 4500 euros indemnities for participation in research involving human beings in the 12 previous months, including participation in the present study. * Subject suffering from dysmorphophobia or having an unreasonable expectation about the treatment results. * Intensive exposure to sunlight or UV-rays within the previous month and foreseen during the study. * Subject with a tattoo, a scar, moles or too many hairs or anything on the face which may interfere with the study at the investigator appreciation. * Subject having resorbable filling product (e.g., hyaluronic acid) injections, a laser treatment, an ultrasound-based treatment a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to study start. * Subjects having received botulinum toxin in the face within the 6 previous months. * Subject having received mesotherapy products in the face within the 3 previous months. * Subject having done a superficial or medium peeling or a superficial scrub on the face within the 2 previous months. * Subject using cosmetic products with alpha hydroxy acids (AHA). * Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand). * Subject having received injections of permanent (e.g., acrylate polymers, silicone, polytetrafluoroethylene) or semi-permanent filling on the face. * Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day). In terms of associated pathology * Subject with ongoing and/or uncontrolled and/or recently recovered (\<6 months) depression or psychiatric disorders or any other disorder that may pose a health risk to the subject in the study and/or may have an impact on the study assessments. * Subject with severe, ongoing and uncontrolled diseases such as malignancy or history of malignancy, type I diabetes, liver failure, renal failure, lung/heart disease, neoplasia, malignant blood disease, tumor, HIV, or other major disease (e.g., systemic fungal infection). * Subject with recurrent porphyria, coronary insufficiency, ventricular rhythm disorders, severe hypertension, obstructive cardiomyopathy, hyperthyroidism. * Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk. * Subject with known history of or suffering from autoimmune disease and/or immune deficiency. * Subject with current cutaneous inflammatory or infectious processes (e.g., acne, herpes, mycosis, papilloma, chronic eczema, atopic dermatitis …), abscess, unhealed wound, or a cancerous or precancerous lesion on the face. * Subject with multiple allergies, anaphylactic shock history, evolutive allergic pathologies. * Subject having history of allergy or hypersensitivity to one of the components of the tested device * Subject having history of hypersensitivity to lidocaine and/or prilocaine or local anaesthetics of amide type or one of the excipients of EMLA® 5% cream. * Subject having history of hypersensitivity to chlorhexidine (or similar product) or one of the excipients of alcoholic chlorhexidine 0.5%. * Subject predisposed to keloids or hypertrophic scarring. * Subject with coagulation and/or homeostasis disorders. * Subject with pigmentation disorders. Related to previous or ongoing treatment * Subject under anti-coagulant treatment (such as aspirin, nonsteroidal anti-inflammatory drugs) or treatment liable to interfere with the healing process or hemostasis, during the previous month and during the study * Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk. * Subject undergoing a topical (on the face) or systemic treatment: * anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study; * immunosuppressors and/or corticoids during the 4 previous weeks and during the study; * retinoids during the 6 previous months and during the study